CAS: 2247890-13-5

BAY-6035

BAY-6035 is an inhibitor of SET and MYND domain-containing protein 3 (SMYD3). BAY-6035 has more than 100-fold selectivity over other histone methyltransferases.

BAY 6035 is an anticoagulant drug, which is a synthetic compound developed for clinical and research purposes. It is derived from chemical synthesis, designed to interact specifically with elements of the coagulation cascade. BAY 6035 functions by inhibiting factor Xa, an enzyme critical in the pathway leading to the formation of thrombin. By targeting factor Xa, it effectively reduces thrombin generation, consequently decreasing fibrin formation and clot development. The applications of BAY 6035 are primarily in contexts requiring the prevention of thrombosis. It is used in the management of conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism, where unwanted clot formation poses significant health risks. In a research setting, BAY 6035 is utilized to study coagulation mechanisms and to evaluate the efficacy and safety of anticoagulation therapy. It offers a potent tool for scientists examining the detailed pathways of hemostasis and its disorders. Importantly, the utilization of BAY 6035 contributes significantly to advancing medical understanding and treatment of thrombotic conditions.